|
14.01.2025 13:37:21
|
ORIC Pharma Stock Climbs On Clinical Supply Deal With J&J's Janssen For ORIC-114
(RTTNews) - Shares of ORIC Pharmaceuticals, Inc. (ORIC) gained around 8 percent on Monday's regular trading on the Nasdaq and is currently 10 percent higher in the pre-market activity, after the clinical stage oncology company announced that it has entered into a supply agreement with Janssen Research & Development LLC, affiliated to drug major Johnson & Johnson (JNJ), to evaluate ORIC-114.
Under the deal, the companies will study ORIC-114, a brain penetrant, orally bioavailable, irreversible EGFR/HER2 inhibitor, in combination with subcutaneous amivantamab, Johnson & Johnson's fully-human EGFR-MET bispecific antibody, for the first-line treatment of patients with advanced non-small cell lung cancer or NSCLC with EGFR exon 20 insertion mutations.
ORIC said it expects to initiate the combination Phase 1b trial to evaluate the safety and tolerability of ORIC-114 in combination with SC amivantamab for the first-line treatment of patients with advanced NSCLC with EGFR exon 20 insertion mutations in the first quarter of 2025.
The primary objectives of the Phase 1b trial are to determine the provisional recommended Phase 2 dose or RP2D for the combination, and additional objectives include assessment of efficacy and further characterization of the safety profile of ORIC-114 in combination with SC amivantamab.
ORIC will conduct and sponsor the trial and Johnson & Johnson will provide SC amivantamab.
The company expects to report initial data from the trial in mid-2026.
ORIC maintains development and commercial rights to ORIC-114 and is free to expand the program in combination with other agents.
The company noted that ORIC-114 has already demonstrated encouraging systemic and intracranial activity in heavily pre-treated patients with EGFR/HER2 mutated NSCLC.
Jacob Chacko, ORICchief executive officer, said, "Given the prevalence of brain metastases across all lines of EGFR exon 20 NSCLC, we aim to further explore ORIC-114s emerging profile in the first-line setting both as a monotherapy and in combination with SC amivantamab."
On the Nasdaq, ORIC Pharma shares closed Monday's regular trading at $8.60, up 8.04 percent. In pre-market activity, the shares were gaining around 10.4 percent to trade at $9.49.
For More Such Health News, visit rttnews.com https://www.rttnews.com/content/health.aspx
Nachrichten zu ORIC Pharmaceuticals Inc Registered Shs
| Keine Nachrichten verfügbar. |
Analysen zu ORIC Pharmaceuticals Inc Registered Shs
DeepSeek: KI-Branche unter Druck – Wall Street Live mit Tim Schäfer
🚨🚨🚨 China schlägt Nvidia: Billig-KI schockt die Tech-Welt und lässt Aktien taumeln! 🤔
In unserer heutigen Folge spricht Tim Schäfer im Interview mit David Kunz, COO der BX Swiss AG über das kürzlich erschienene DeepSeek und welche Auswirkungen die künstliche Intelligenz diese Woche auf die Märkte hatte. Welche Hintergründe hat DeepSeek, wie sieht die langfristige Entwicklung in der Branche aus und warum ist Europa praktisch von der Entwicklung abgehängt?
In unserem zweiwöchigen Format „Wall Street Live“ mit Tim Schäfer behandeln wir Topaktuelle Themen des Marktgeschehens.
👉🏽 https://bxplus.ch/wall-street-live-mit-tim-schaefer/
Inside Trading & Investment
Mini-Futures auf SMI
Inside Fonds
Aktien in diesem Artikel
| Johnson & Johnson | 135.40 | -2.71% |
|
| ORIC Pharmaceuticals Inc Registered Shs | 10.45 | -2.88% |
|
Meistgelesene Nachrichten
Top-Rankings
Börse aktuell - Live Ticker
US-Börsen mit Minus ins Wochenende -- SMI und DAX fallen vor dem Wochenende letztlich zurück -- Tokio schliesst in GrünDer heimische Aktienmarkt gab seine zwischenzeitlichen Gewinne vollständig ab. Der deutsche Aktienmarkt bewegte sich unterdessen um die Nulllinie. An der Wall Street geht es am Freitag aufwärts. Die Börse in Japan präsentierte sich im Freitagshandel fester.
finanzen.net News
| Datum | Titel |
|---|---|
|
{{ARTIKEL.NEWS.HEAD.DATUM | date : "HH:mm" }}
|
{{ARTIKEL.NEWS.BODY.TITEL}} |